Pharma Firms Will ‘Walk Away’ From Gene Therapies Unless Payers Share Risk

The EU, US and other countries with similar health care systems must “take responsibility” for the financial and health risks involved in getting innovative drugs, such as gene therapies, to market, says an academic expert who has worked in the advanced therapy field.